Novartis will acquire the CNS disorder drug developer after backing its series B round in late 2018, also providing an exit for Access Industries.

The Alphabet and Tencent-backed robotic process automation technology provider was valued at $10.2bn in its last funding round.

BBVA, New York Stock Exchange, NTT Docomo and USAA could be in line to exit the crypto trading platform developer, which was valued at $8bn two years ago.

The flexible car rental service has agreed to be acquired, having raised nearly $40m from investors including BP, Shell and Channel 4.

BP has acquired a majority stake in the carbon offset project facilitator, just over a year after investing $5m in the company.

The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.

Stanford-StartX Fund is set to exit payment processing technology provider Poynt in an acquisition sized at up to $365m.

The Eli Lilly-backed antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.

Rakuten, Progressive and GV-backed online lending platform developer floated at the bottom of its range before a first-day pop.

Pfizer Ventures-backed cancer drug developer BioAtla's shares popped on its first day of trading yesterday following a $189m initial public offering.